Observational Study of Real-World Factor Utilization and Health Outcomes in Patients with Hemophilia in Canada

Conclusion: We found that a cohort of Canadian patients with moderate-severe hemophilia appear to be switched to rFVIIIFc/ rFIXFc on the basis of patient convenience, expected improvement in HRQoL, and prophylaxis adherence. Although limited by a small sample size, there appears to be no significant within-individual changes in hemophilia specific HRQoL, chronic pain, and treatment satisfaction. Data collection is ongoing (expected completion date September 2019) to provide additional insight on various clinical and patient reported outcomes in the larger study population.DisclosuresSun: Novo Nordisk: Honoraria; Octapharma: Research Funding. Poon: Novo Nordisk: Consultancy, Speakers Bureau; CSL Behring: Consultancy, Research Funding; Bayer: Research Funding, Speakers Bureau; Octapharma: Consultancy; Pfizer: Consultancy, Speakers Bureau; Roche: Consultancy; Biogen: Consultancy; Baxalta/ Shire: Consultancy. Lee: Bayer: Other: Project based funding from Bayer Hemophilia Awards Program; Bioverativ: Research Funding. Robinson: Roche: Honoraria, Other: Advisory board, Research Funding, Speakers Bureau; Celgene: Other: Advisory board, Speakers Bureau. Wu: Bayer: Honoraria, Other: Advisory board, Research Funding; Shire: Honoraria; Pfizer: Other: Advisory board; Bioverativ: Honoraria, Other: Advisory board; Novo Nordisk: Honoraria, Other: Advisory board; Octapharma: Honoraria, Other: Advisory board; CSL Behring: Honoraria, Other: Advisory board. Iorio: CSL: Other: Alfonso Iorio's Ins...
Source: Blood - Category: Hematology Authors: Tags: 903. Outcomes Research-Non-Malignant Hematology: Poster III Source Type: research